Co-Authors
This is a "connection" page, showing publications co-authored by Andrew South and Matthew Sparks.
Connection Strength
1.948
-
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 06; 16(6):305-307.
Score: 0.885
-
Renin-angiotensin system blockade in the COVID-19 pandemic. Clin Kidney J. 2021 Mar; 14(Suppl 1):i48-i59.
Score: 0.232
-
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. Hypertension. 2020 11; 76(5):1350-1367.
Score: 0.226
-
Rigor before speculation in COVID-19 therapy. Am J Physiol Lung Cell Mol Physiol. 2020 05 01; 318(5):L1027-L1028.
Score: 0.220
-
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clin J Am Soc Nephrol. 2020 May 07; 15(5):714-716.
Score: 0.218
-
Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. Adv Chronic Kidney Dis. 2020 09; 27(5):404-411.
Score: 0.056
-
Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". Circ Res. 2020 06 05; 126(12):e140-e141.
Score: 0.055
-
Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. J Am Soc Nephrol. 2020 07; 31(7):1380-1383.
Score: 0.055